Treatment of non-fluctuating progressive dystonia: a neuropharmacological approach.
HVA and 5-HIAA in CSF were determined in five patients with non-fluctuating progressive dystonia before and after treatment with L-Dopa. The response to L-Dopa was unequivocally favourable in one patient. The HVA-level in her CSF was significantly reduced before treatment, whereas in the other four non-responding patients the pre-treatment HVA was normal. It is postulated, that the biochemical delineation of clinical responsiveness to a neurotransmitter may provide useful clues towards the classification of extrapyramidal disease in childhood.
D000293:Adolescent; D001479:Basal Ganglia / Q000187:drug effects*; D002648:Child; D002851:Chromatography, High Pressure Liquid; D004421:Dystonia / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D009435:Synaptic Transmission / Q000187:drug effects*; D013577:Syndrome
D010648:Phenylacetates; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D006719:Homovanillic Acid